🔗 Share this article

While America undertakes sweeping changes to its vaccine recommendations, a particular individual has emerged somewhat surprisingly: Høeg, a Danish American sports medicine doctor and epidemiologist who initially gained attention by casting doubt on Covid vaccinations throughout the global health crisis and has zeroed in on potential fatalities after Covid vaccination in her short tenure at the Food and Drug Administration.

Scheduled Shifts to Childhood Vaccine Schedule

Health officials had intended to reveal radical revisions to the pediatric vaccination calendar earlier this month, aligning the US with the Danish national calendar, sources say – a substantial departure that would place the US at odds with a large portion of the world with no evidence for benefit. The announcement has been postponed until the coming year.

Instead of the director of the vaccine center, Tracy Beth Høeg is scheduled to address the audience at the gathering. She was just designated temporary leader of the FDA’s CDER, the fifth appointee to head the division this calendar year.

A Shift at the Agency

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it points to a increased emphasis upon reevaluating long-standing immunizations at the FDA.

The new acting director has frequently advocated for halting specific pediatric shot schedules in the US in order to be more in line with Denmark, a society with comprehensive healthcare and a number of inhabitants approximately the population of the state of Wisconsin.

So far public appearances, she has continued to focus on vaccines – traditionally the responsibility of Dr. Prasad, chief of the FDA’s CBER – instead of drug regulation.

Questions Over Qualifications

Høeg has little discernible experience in medication creation, oversight or administrative roles, which has been customary for former leaders of the biologics center. She has been employed at the FDA as a key advisor to the agency head and CBER since earlier this year.

“It seems she lacks to have the necessary background” for overseeing the CDER, stated Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in leading a sizeable institution. She is not an expert in drug approvals.”

Previous directors of CBER would “understand legal statutes and the research of drug development”, said Janet Woodcock. “Clearly, she lacks the sort of resume that prior appointees who headed CBER have had.”

This division has an immense portfolio at the agency, she stated.

“The public just zeroes in on the new drug program, but the generic program approves thousands of generic medications. There’s a biosimilars division, over-the-counter program and more, and every single one need to be looked after,” she noted. “The thing you neglect, that’s the thing that I always told people is going to cause problems.”

Furthermore, a substantial leadership component to the role, which oversees over 5,000 employees. “It’s a enormous administrative position, if you perform it correctly,” Woodcock added.

Response and Contentious Programs

Regarding concerns about Dr. Høeg's credentials and whether this appointment signifies more teamwork among agency officials on immunizations, a press secretary responded that the “questions stem from flawed assumptions”.

“Her experience aligns with the duties of her position,” the representative stated, pointing to the period Dr. Høeg spent guiding the agency head on “pharmaceutical safety and approval science, including computational safety modeling and vaccine surveillance”.

As acting director, Høeg takes over the agency head's recently launched expedited review system, a contentious rapid drug-approval program that apparently worried her predecessors. “By what process are these therapies being selected for this fast-track system? Who takes the calls?” Howard asked. “There is a lot of confidentiality happening at the agency right now.”

In general, he stated, “the Food and Drug Administration looks to be trending towards laxer rules of most medications, except for vaccines.”

Established Past Work on Vaccines

Regarding vaccines, Dr. Høeg has a clearer, if concerning, track record, some experts said. She released a study using unconfirmed crowd-sourced reports to estimate the frequency of myocarditis after Covid immunization. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have changed statistics to indicate Covid vaccines are riskier than they are.

Part of her “wish list” for the incoming administration featured changing rules for new vaccines and halting “unnecessary” immunizations, she remarked after the election on a audio program. At the FDA, Dr. Høeg has according to sources proposed preventing adolescent males from getting Covid vaccinations.

“She is an thorough ideologue who commences with her beliefs and tailors the evidence to retrofit the science in a extremely disingenuous, dishonest way,” Dr. Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg aligned with other skeptics, {like|